OUR PRODUCTS

HYDRATE IT
with Juvéderm® VOLITE1,*

SMOOTH IT
with Juvéderm® VOLBELLA2,*

FILL IT
with Juvéderm® VOLIFT3,*

VOLUMISE IT
with Juvéderm® VOLUMA4,*

SCULPT IT
with Juvéderm® VOLUX5,*

Model treated with JUVÉDERM ®. Results may vary.

* Products contain lidocaine,1–5 the addition of which does not alter the physical properties of JUVÉDERM ® products. 6 In
this document, Juvéderm ® VOLBELLA with lidocaine, Juvéderm ® VOLIFT with lidocaine and Juvéderm ® VOLUMA with ID-JUV-2050073
lidocaine will be referred to as Juvéderm ® VOLBELLA, Juvéderm ® VOLIFT and Juvéderm ® VOLUMA, respectively.
 ®

THE VYCROSS® COLLECTION: DESIGNED AND TAILORED

FOR THE MOST TREATED AREAS OF THE FACE14,*

Up to 24
months

For illustrative purposes only. For illustrative purposes only.

VYCROSS® is a collection of Duration from 9 to 24 months, Thorough tissue integration, 29–32,‡

products that can fill lines, add depending on which filler you which may contribute to the natural
volume, shape the face and improve choose18,20,21,25,26,28 look and feel assessed as a result
your patients’ skin quality, depending of treatment17,18,29,32,33
on the treatment chosen1–5,†

* Based on market research involving 756 healthcare professionals from 12 international markets.14
† Skin qualit y is defined a s smoothness (absence of fine lines), hydr ation and ela sticit y. 20 Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness
improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%). 20
‡ Tissue integration was demonstrated by Juvéderm ® VOLBELLA, Juvéderm ® VOLIFT, Juvéderm ® VOLUMA and Juvéderm ® VOLUX at 4 weeks in animal in vivo studies. 29–32

2
JUVÉDERM® IT WITH OUR

VAL!
RANGE OF PRODUCTS

AR R I
N EW
We’re the world’s number one brand
of hyaluronic acid (HA) facial fillers.7,*
Built on a long heritage of quality, science and meaningful
innovation, 8 we’ve created a comprehensive collection
1
of HA fillers1–5,9–13 that are designed and tailored for the
most treated areas of the face.14,† Juvéderm® VOLUX – our most
Our two patented technologies, HYLACROSS® and cohesive, 22,‡ elastic, 23,‡ concentrated
VYCROSS®,15 mean you can have fillers with a variety of HA filler5 – is here!
different characteristics to choose and create bespoke Juvéderm® VOLUX has been
treatment plans for patients16 – for natural-looking designed to restore and
changes17,18 with lasting results15,19–21 and satisfaction.18,20,21 create volume in the chin
and jaw area. 21,§

* B a sed on healthcare professional (HCP) tr acking mar ket research , from over 1000 HCPs in the largest 13 aesthetic mar ket s wor ldwide.7
† B a sed on mar ket research involving 756 healthcare professionals from 12 inter nationalmar ket s .14
‡ Rheological proper ties of gels are char ac ter is tics to descr ibe their phy sical responses to applied forces in vitro and should not be
individually translated to clinical performance. 22,23
§ Clinical study assessed lower face as chin and jaw area. 21

3
When you want to When you want to When you want to When you want to When you want
enhance skin refine features and fill lines and correct mid-face to define the
quality1,20,24,* reduce fine lines2,18 shape features3 volume4,25,26 lower face5,21,27,†

* Skin qualit y is defined a s smoothness (absence of fine lines), hydr ation and ela sticit y. 20 Investigator-assessed cheek skin texture (primary endpoint) as a Models treated with JUVÉDERM ®.
measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%). 20 Results may vary.
† Clinical study a ssessed lower f ace a s chin and jaw area . 21

4
Images are for illustrative purposes
only. Not an accurate
representation of the data.

When you When you When you When you When you
want to want to want to want to want to
enhance correct define
skin features and shape mid-face the lower
quality 1,20,24,* and reduce features 3 volume 4,25-26 face 5,21,27,†
e lines 2,18
+ hands + décolletage

Duration 9
‡
12 §
24 ¶
(months)18,20-21,25,26,28,34-36,44
18 1 8 – 24

Superficial Subcutaneous
Deep dermis Subcutaneous
Injection depth 1–5 Intradermal Mid-dermis
Lips mucosa
Deep dermis
Supraperiostal
Lips mucosa Upper periostea

HA concentration
(mg/mL) + 0.3% lidocaine1–5 12 15 17.5 20 25
Extrusion force at
50 mm/min (N)45, ‫ۅ‬
19.7 13.8 18.6 15.8 16.5
32G1/2” needle 30G1/2” needle 30G1/2” needle 27G1/2” needle 27G1/2” needle

Cohesivity
(grams-force [gmf])22,** 12 18 24 35 93
Elasticity
(G’ at 5 Hz, pascals [Pa]23, ** 166 274 317 353 665
Lift capacity 46

HA, hyaluronic acid. Duration dependent on treatment area.
* Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity.
Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness
improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9
(15.8%).
† Clinical study assessed lower face as chin and jaw area.23
‡ Studies evaluating the duration of Juvéderm® VOLITE used Juvéderm®
VOLITE B (without lidocaine).32
§ 18-month duration in nasolabial folds (NLFs) from clinical data. Within 4 weeks after the Month
9, 12, or 15 visits, patients could request a single, unilateral treatment to correct clinically
significant asymmetry (at least 1-point difference in NLF severity between NLFs, based on the
Evaluating Investigator assessment). 22
¶ Based on comparative preclinical in vitro testing and results from repeat
treatment data, added to Juvéderm® VOLUX clinical study showing duration beyond 18 months after
initial treatment or initial + top-up treatment in the chin and jaw, as well as clinical results for predicate
device Juvéderm® VOLUMA
with lidocaine showing 24 month duration in the mid-face established Juvéderm®
VOLUX as having anin situ duration of 18–24 months.31
‫ ۅ‬An extrusion force of <20 N is classified as ‘low’ when injected at a fixed rate of
50 mm/min.30 Extrusion force of gels is a characteristic to describe their physical responses to
applied forces upon injection and should not be individually translated into clinical
performance.33
** Rheological properties of gels are characteristics to describe their physical
responses to applied forcesin vitro and should not be individually translated to clinical
performance.26,27

5
JUVÉDERM ®IT WITH
THE VYCROSS®COLLECTION
Juvéderm® VOLITE Juvéderm® VOLBELLA Juvéderm® VOLIFT Juvéderm® VOLUMA
12 mg/mL, 0.3% lidocaine1 15 mg/mL, 0.3% lidocaine2 17.5 mg/mL, 0.3% lidocaine 3 20 mg/mL, 0.3% lidocaine 4

For enhancing skin quality 1,20,24,* For refining features and reducing For filling lines and shaping features 3 For correcting mid-face volume 4,25,26
fine lines2,18

Face, hands, neck, décolletage Forehead lines, periorbital lines, Forehead lines, eyebrows, cheeks, Temple, cheeks and cheekbones
glabellar lines, tear troughs, nasolabial folds, lips and perioral
lips and perioral lines lines, marionette lines, chin

Intradermal1 Superficial, mid-dermis, lips mucosa 2 Deep dermis, lips mucosa3 Subcutaneous, upper periostea,
deep dermis 4

Up to 9 months’ duration 9 Up to 12 months’ Up to 18 months’ Up to 24 months’ 24

of dermal hydration20,† duration18,34
12 duration28,35,‡
18 duration25,26,§

2 x 1 mL, 4 x 32 G½”1 2 x 1 mL, 4 x 30 G½”2 2 x 1 mL, 4 x 30 G½”3 2 x 1 mL, 4 x 27 G½”4

Registration Number: AKL 31602810131 Registration Number: AKL 31602812536 Registration Number: AKL 31602812482 Registration Number: AKL 31602812481

* Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity. 20 Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%),
Month 6 (34.9%) and Month 9 (15.8%). 20 † Cheek skin hydration, as measured by the MoistureMeter ® D instrument, significantly improved from baseline at Months 1, 4, 6 and 9. 20 ‡ 18-month duration in nasolabial folds (NLFs) from clinical data.
Within 4 weeks after the Month 9, 12, or 15 visits, patients could request a single, unilateral treatment to correct clinically significant asymmetry (at least 1-point difference in NLF severity between NLFs, based on the Evaluating Investigator
assessment). 28 § One of the studies was conducted using Juvéderm ® VOLUMA without lidocaine. 25 The addition of lidocaine does not alter the physical properties of JUVÉDERM ® products. 6

6
JUVÉDERM ®VOLUX: AN EVOLUTION
WITHIN THE VYCROSS ®COLLECTION
Juvéderm® VOLUX5 Juvéderm® VOLUX has been designed to restore and create volume
25 mg/mL, 0.3% lidocaine in the chin and jaw area21,* for 18–24 months. 21,36,† Our new addition:
For defining the lower face5,21,27,* • Has the highest levels of cohesivity and elasticity within
the VYCROSS® collection22,23,‡
Pogonion, mentum, pre-jowl sulci, • Is designed for lower face areas needing increased projection
sublabial (mental) crease
and defining – chin and jaw area21,*
• Delivered thorough tissue integration (in a rat model),31 which
Subcutaneous, supraperiostal 5
may contribute to the natural look and feel assessed as a
result of treatment32
18–24 months’ duration21,36,†
18–24

2 x 1 mL, 4 x 27 G½”5

Registration Number: AKL 31602810131

* Clinical study assessed lower face as chin and jaw area. 21

† Based on comparative preclinical in vitro testing and results from repeat treatment data, added to Juvéderm ® VOLUX clinical study showing duration beyond 18 months after initial treatment or initial + top-up treatment in the chin and jaw,
as well as clinical results for predicate device Juvéderm ® VOLUMA with lidocaine showing 24 month duration in the mid-face established Juvéderm ® VOLUX as having an in situ dura tion of 18–24 months.36
‡ Rheological properties of gels are characteristics to describe their physical responses to applied forces in vitro and should not be individually translated to clinical performance. 22,23

7
WHY JUVÉDERM® IT?

Trust in JUVÉDERM®, the world’s Allergan is built on a long heritage of quality,

number one brand of HA facial fillers7,* science and meaningful innovation8

* Based on healthcare professional (HCP) tracking market research, from over 1000 HCPs in the largest 13 aesthetic markets worldwide. 7
 For illustrative purposes only. For illustrative purposes only.

The JUVÉDERM® collection of ... and feature thorough tissue

HA fillers1–5,9–13 is designed and integration,29–32,† which may contribute
tailored for the most treated to the natural look and feel assessed as a
areas of the face…14,* result of treatment17,18,29,32,33 that patients
can be satisfied with.18,20, 21, 25,26,28,41
* Based on market research involving 756 healthcare professionals from 12 international markets.14
† Tissue integration was demonstrated by Juvéderm ® ULTRA XC, Juvéderm® ULTRA PLUS XC, Juvéderm ® VOLBELLA, Juvéderm ® VOLIFT, Juvéderm ® VOLUMA and Juvéderm ® VOLUX at 4 weeks in animal in vivo studies. 29–32
THE NEW SYRINGE
FROM JUVÉDERM®
EMPLOY YOUR SKILL AND ARTISTRY
WITH COMFORT AND CONTROL42,*

• Improved ease of aspiration. 42 Aspiration can help

minimise the risk of vascular complications 43
• Improved injection comfort 42
• Minimal muscle fatigue42
• Lower exertion pressure required for serial punctures 42

For illustrative purposes only.

* Compared with the older, existing JUVÉDERM ® syringe design (standard). 42

14
REFERENCES
1. Juvéderm® VOLITE DFU. 73755IN10. Revision 16-07-2019. 26. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–12.
2. Juvéderm® VOLBELLA with lidocaine DFU. 73754IN10. Revision 16-07-2019. 27. Ogilvie P et al. Poster Presentation at Aesthetic & Anti-Aging Medicine World Congress
3. Juvéderm® VOLIFT with lidocaine DFU. 73753IN10. Revision 16-07-2019. (AMWC), Monte Carlo, Monaco; 2018.
4. Juvéderm® VOLUMA with lidocaine DFU. 73760IN10. Revision 16-07-2019. 28. Allergan. Unpublished Data. INT/0214/2017(2). Juvéderm® VOLIFT XC US clinical study
5. Juvéderm® VOLUX DFU. 73757IN10. Revision 16-07-2019. results (V17-001). Apr 2019.
6. Raspaldo H et al. J Cosmet Dermatol. 2010;9:11–15. 29. Allergan. Data on File. INT/0773/2016(1). Juvéderm® VOLITE B without
7. Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM®, lidocaine. Sep 2018.
the world’s leading brand of hyaluronic acid facial fillers. Feb 2019. 30. Allergan. Unpublished Data. INT/0009/2018(1)a(1). JUVÉDERM® extrusion
8. Stephens H. 2000. Allergan’s first fifty years. Lyme, Conn: Greenwich Pub. Group force data. May 2018.
9. Juvéderm® ULTRA 2 DFU. 72345JR15. Revision 2017-07-19. 31. Allergan. Unpublished Data. INT/0129/2019. Juvéderm® VYCROSS collection
10. Juvéderm® ULTRA 3 DFU. 72490JR13. Revision 2017-07-19. lift capacity. Feb 2019.
11. Juvéderm® ULTRA 4 DFU. 72488JR13. Revision 2017-07-19. 32. Allergan. Data on File. INT/0663/2018. Juvéderm® VOLUX final clinical evaluation report.
12. Juvéderm® ULTRA XC DFU. 72360EC12. Revision 2016-02-23. Oct 2018.
13. Juvéderm® ULTRA PLUS XC DFU. 72361EC12. Revision 2016-02-23. 33. Baumann LS. Dermatol Surg. 2007;33(Suppl 2):S128–35.
14. Allergan. Unpublished Data. INT/0023/2017(1). The most treated areas of the face. 34. Niforos F et al. Dermatol Surg. 2017;43:1271–80.
Feb 2019. 35. Allergan. Data on File. INT/0607/2017. Juvéderm® VOLIFT NLFSS responder rates (S17L-
15. Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139S–48S. 001). Aug 2017.
16. Bernardin A et al. Poster Presentation at the Anti-Aging Medicine European Congress 36. Allergan. Data on File. INT/0074/2019. Juvéderm® VOLUX final clinical evaluation report.
(AMEC), Monte Carlo, Monaco; 2013. Jan 2019.
17. Philipp-Dormston WG et al. J Cosmet Dermatol. 2014;13:125–34. 37. Wahl G. J Cosmet Dermatol. 2008;7:298–303.
18. Eccleston D and Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167–72. 38. Levy PM et al. Dermatol Surg. 2009;35(Suppl 1):332–37.
19. Pinsky MA et al. Aesthet Surg J. 2008;28:17–23. 39. Goodman GJ et al. Clin Cosmet Investig Dermatol. 2011;4:197–205.
20. Niforos F et al. Poster Presentation at Beauty Through Science (BTS) Congress, 40. Allergan. Data on File. INT/0942/2017. JUVÉDERM® ULTRA ranges. Oct 2017.
Stockholm, Sweden; 2017. 41. Hoffman K. for the JUVÉDERM® VOLUMA Study Investigators Group.
21. Allergan. Data on File. INT/0654/2018. Juvéderm® VOLUX final clinical study report BMC Dermatol. 2009;9:9.
& clinical evaluation report – efficacy and duration data. Oct 2018. 42. Allergan. Unpublished Data. INT/0079/2017(1). JUVÉDERM® syringe, ergonomic
22. Allergan. Unpublished Data. INT/0011/2018a(1). JUVÉDERM® gel cohesivity data. testing results. Apr 2019.
May 2018. 43. Abduljabbar MH et al. J Dermatol Dermatol Surg. 2016;20:100–06.
23. Allergan. Unpublished Data. INT/0141/2019. JUVÉDERM® (gel elasticity G’) data. Mar 2019. 44. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–81.
24. Allergan. Unpublished Data. INT/0078/2017(1). Juvéderm® VOLITE treatment area. 45. Allergan. Data on File. INT/0650/2017. JUVÉDERM® tissue integration images. Aug 2017.
Mar 2019. 46. Allergan. Unpublished Data. INT/0314/2018(1). Juvéderm® VOLUX tissue integration.
25. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81–89. May 2018.
WHEN YOU WANT TO
JUVÉDERM® IT...
This brochure has been created to help with
your ordering needs. Whether you’re looking to
restock your most popular facial filler treatments
or want to JUVÉDERM® IT with the entire range,
all of our facial fillers are available to order,
including our new Juvéderm® VOLUX product.

20